References
- Amundson SA, Myers TG, Fornace AJ (1998). Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene, 17, 3287-99. https://doi.org/10.1038/sj.onc.1202576
- Bridges KA, Hirai H, Buser CA, et al (2011). MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res, 17, 5638-48. https://doi.org/10.1158/1078-0432.CCR-11-0650
- Bucher N, Britten CD (2008). G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer, 98, 523-8. https://doi.org/10.1038/sj.bjc.6604208
- Canman CE, Gilmer TM, Coutts SB, et al (1995). Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev, 9, 600-11. https://doi.org/10.1101/gad.9.5.600
- Carrassa L, Chila R, Lupi M, et al (2012). Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 11, 2507-17. https://doi.org/10.4161/cc.20899
- Castedo M, Perfettini JL, Roumier T, et al (2004). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene, 23, 4362-70. https://doi.org/10.1038/sj.onc.1207572
- Chen PL, Chen YM, Bookstein R, et al (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-80. https://doi.org/10.1126/science.2274789
- Dixon H, Norbury CJ (2002). Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle, 1, 362-8. https://doi.org/10.4161/cc.1.6.257
- Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95, 1482-5. https://doi.org/10.1093/jnci/djg050
- Fujisawa T, Watanabe J, Kamata Y, et al (2003). VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells. Hum Cell, 16, 47-54. https://doi.org/10.1111/j.1749-0774.2003.tb00128.x
- Gottlieb E, Haffner R, King A, et al (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J, 16, 1381-90. https://doi.org/10.1093/emboj/16.6.1381
- Gottlieb E, Oren M (1998). p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J, 17, 3587-96. https://doi.org/10.1093/emboj/17.13.3587
- Hirakawa S, Kodama S, Kunstfeld R, et al (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med, 201, 1089-99. https://doi.org/10.1084/jem.20041896
- Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer, 6, 391-401. https://doi.org/10.3816/CBC.2005.n.043
- Igarashi M, Nagata A, Jinno S, et al (1991). Wee1(+)-like gene in human cells. Nature, 353, 80-3. https://doi.org/10.1038/353080a0
- Iorns E, Lord CJ, Grigoriadis A, et al (2009). Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One, 4, 5120. https://doi.org/10.1371/journal.pone.0005120
- Jiang M, Milner J (2003). Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev, 17, 832-7. https://doi.org/10.1101/gad.252603
- Kelly PN, Strasser A (2011). The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414-24. https://doi.org/10.1038/cdd.2011.17
- Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325. https://doi.org/10.1677/erc.1.01172
- Lai Z, Ferry KV, Diamond MA, et al (2001). Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem, 276, 31357-67. https://doi.org/10.1074/jbc.M011517200
- Mandal S, Berube G, Asselin E, et al (2007). A new platinum complex of triazine demonstrates G1 arrest with novel biological profile in human breast cancer cell line, MDA-MB-468. Bioorg Med Chem Lett, 17, 2139-45. https://doi.org/10.1016/j.bmcl.2007.01.116
- Mir SE, De Witt Hamer PC, Krawczyk PM, et al (2010). In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell, 18, 244-57. https://doi.org/10.1016/j.ccr.2010.08.011
- Mukhopadhyay D, Tsiokas L, Sukhatme VP (1995). Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res, 55, 6161-5.
- Murrow LM, Garimella SV, Jones TL, et al (2010). Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 122, 347-57. https://doi.org/10.1007/s10549-009-0571-2
- Pal S, Datta K, Mukhopadhyay D (2001). Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res, 61, 6952-7.
- Porebska I, Wyrodek E, Kosacka M, et al (2006). Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo, 20, 599-604.
- Prasad KA, Church JG (1997). EGF effects on p53 in MDA-468 human breast cancer cells: implications for G1 arrest. Cell Prolif, 30, 81-94. https://doi.org/10.1111/j.1365-2184.1997.tb00924.x
- Schlotter CM, Vogt U, Allgayer H, et al (2008). Molecular targeted therapies for breast cancer treatment. Breast Cancer Res, 10, 211. https://doi.org/10.1186/bcr2112
- Tibes R, Bogenberger JM, Chaudhuri L, et al (2012). RNAi screening of the kinome with cytarabine in leukemias. Blood, 119, 2863-72. https://doi.org/10.1182/blood-2011-07-367557
- Venkatachalam S, Tyner SD, Pickering CR, et al (2001). Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol, 29, 147-54. https://doi.org/10.1080/019262301753178555
- Vousden KH, Lu X (2002). Live or let die: the cell’s response to p53. Nat Rev Cancer, 2, 594-604. https://doi.org/10.1038/nrc864
- Wang Y, Decker SJ, Sebolt-Leopold J (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther, 3, 305-13. https://doi.org/10.4161/cbt.3.3.697
Cited by
- PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells vol.12, pp.1, 2014, https://doi.org/10.1186/s12951-014-0032-x
- Involvement of multiple cellular pathways in regulating resistance to tamoxifen in BIK-suppressed MCF-7 cells vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3374-6
- Targeting protein kinase-b3 (akt3) signaling in melanoma vol.21, pp.3, 2017, https://doi.org/10.1080/14728222.2017.1279147
- MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1 vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317706224